Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025

Carisma Therapeutics Inc.

2024-Q3 EPS reported -$1.04 revenue$16,000,000

Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.
Cash and equivalents $26.9M as of Sep 30, 2024, down from $40.4M at Jun 30; expected runway into Q3 2025.
Phase 1 CT-0525 (HER2 CAR-Monocyte) initial data for Cohorts 1 and 2 expected Q1 2025; protocol amended for repeat dosing with pembrolizumab.
Expanded Moderna collaboration to include two autoimmune targets; retains rights beyond those.
Liver fibrosis development candidate nomination expected Q1 2025; preclinical data to be presented at AASLD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.